Syndax Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Syndax Pharmaceuticals wird ein jährliches Gewinn- und Umsatzwachstum von 30.6% bzw. 52.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 34.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -61.2% betragen.

Wichtige Informationen

30.6%

Wachstumsrate der Gewinne

34.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.5%
Wachstumsrate der Einnahmen	52.4%
Zukünftige Eigenkapitalrendite	-61.2%
Analystenabdeckung	Good
Zuletzt aktualisiert	24 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Sep 20

Syndax: Gearing Up For Launches

Jun 21

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Jun 20

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Mar 28

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Mar 04

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Nov 20

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Sep 27

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Aug 07

Syndax Pharmaceuticals: Cash-Rich With 2 Promising Drugs

Apr 08

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:SNDX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	230	-210	-164	-148	11
12/31/2025	103	-297	-228	-240	12
12/31/2024	32	-318	-290	-263	12
6/30/2024	4	-264	-241	-241	N/A
3/31/2024	N/A	-241	-205	-205	N/A
12/31/2023	N/A	-209	-161	-161	N/A
9/30/2023	N/A	-176	-142	-142	N/A
6/30/2023	N/A	-160	-126	-126	N/A
3/31/2023	N/A	-153	-131	-131	N/A
12/31/2022	N/A	-149	-134	-134	N/A
9/30/2022	127	-14	-10	-10	N/A
6/30/2022	139	1	-7	-6	N/A
3/31/2022	139	15	10	10	N/A
12/31/2021	140	25	29	29	N/A
9/30/2021	14	-92	-87	-87	N/A
6/30/2021	2	-91	-81	-81	N/A
3/31/2021	2	-86	-78	-78	N/A
12/31/2020	2	-77	-71	-71	N/A
9/30/2020	2	-71	-68	-68	N/A
6/30/2020	2	-63	-59	-59	N/A
3/31/2020	2	-61	-50	-50	N/A
12/31/2019	2	-56	-51	-51	N/A
9/30/2019	2	-61	-53	-53	N/A
6/30/2019	2	-65	-63	-63	N/A
3/31/2019	2	-69	-66	-65	N/A
12/31/2018	2	-74	-69	-69	N/A
9/30/2018	2	-74	-66	-66	N/A
6/30/2018	2	-72	-58	-58	N/A
3/31/2018	2	-67	N/A	-55	N/A
12/31/2017	2	-61	N/A	-47	N/A
9/30/2017	1	-53	N/A	-45	N/A
6/30/2017	1	-52	N/A	-46	N/A
3/31/2017	1	-47	N/A	-41	N/A
12/31/2016	1	-47	N/A	-35	N/A
9/30/2016	1	-45	N/A	-29	N/A
6/30/2016	1	-87	N/A	-23	N/A
3/31/2016	1	-105	N/A	-20	N/A
12/31/2015	1	-104	N/A	-2	N/A
9/30/2015	0	-100	N/A	-2	N/A
6/30/2015	0	-53	N/A	1	N/A
3/31/2015	N/A	-33	N/A	1	N/A
12/31/2014	N/A	-26	N/A	-14	N/A
9/30/2014	N/A	-31	N/A	-14	N/A
6/30/2014	N/A	-72	N/A	-13	N/A
3/31/2014	N/A	-67	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: SNDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: SNDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: SNDX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: SNDXDie Einnahmen des Unternehmens (52.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.8% pro Jahr).

Hohe Wachstumseinnahmen: SNDXDie Einnahmen des Unternehmens (52.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: SNDX wird voraussichtlich in 3 Jahren unrentabel sein.

Syndax Pharmaceuticals Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 21%

Consensus revenue estimates increase by 12%

Consensus EPS estimates fall by 23%

Consensus revenue estimates decrease by 11%, EPS upgraded

Consensus EPS estimates fall by 21%

Price target increased by 7.6% to US$34.44

Recent updates

Syndax Pharmaceuticals: Navigating Through A Pivotal Year

Incyte and Syndax Pharmaceuticals Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

Consensus revenue estimates fall by 21%

Syndax Announces Pdufa Action Date Extension for Revumenib Nda for Relapsed or Refractory Kmt2ar Acute Leukemia

Syndax Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Index

Consensus revenue estimates increase by 12%

Syndax: Gearing Up For Launches

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

SSyndax Pharmaceuticals, Inc. Presents Updated Positive Data from BEAT AML and Augment-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress

Syndax Pharmaceuticals Announces Plans to Advance into Phase 1b Portion of Trial Evaluating Revumenib in Relapsed or Refractory Metastatic MSS CRC

Syndax Pharmaceuticals, Inc. Announces Board Changes

Syndax Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Syndax Pharmaceuticals, Inc. Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session

Syndax Pharmaceuticals, Inc., Annual General Meeting, May 15, 2024

Syndax Pharmaceuticals, Inc. Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals: Upcoming Q3 PDUFAs Ignite Hope

Syndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia

Syndax Pharmaceuticals, Inc. Announces Executive Changes

Consensus EPS estimates fall by 23%

Here's Why We're Not Too Worried About Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

Syndax Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Syndax Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $199.999985 million.

Syndax Pharmaceuticals Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting

Incyte and Syndax Pharmaceuticals Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host Disease

Is Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Trading At A 46% Discount?

Syndax Pharmaceuticals Announces Results from the Pivotal AGAVE-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease to Be Featured in Plenary Session at the 65th ASH Annual Meeting

Syndax Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Syndax Pharmaceuticals Announces to Initiate Nda Submission of Revumenib in Relapsed/Refractory Kmt2ar Acute Leukemia Under Fda's Real-Time Oncology Review Program

Syndax Pharmaceuticals Announces Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia Meets Primary Endpoint and Stated Interim Analysis

Companies Like Syndax Pharmaceuticals (NASDAQ:SNDX) Are In A Position To Invest In Growth

Director notifies of intention to sell stock

Syndax Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Syndax Pharmaceuticals and Incyte Announce Positive Topline Results from the Pivotal Agave-201 Trial of Axatilimab in Chronic Graft-Versus-Host Disease

Director notifies of intention to sell stock

Consensus revenue estimates decrease by 11%, EPS upgraded

Director exercised options and sold US$715k worth of stock

Director exercised options and sold US$794k worth of stock

Syndax Pharmaceuticals, Inc. Announces Executive Changes

President exercised options and sold US$695k worth of stock

President exercised options and sold US$853k worth of stock

Consensus EPS estimates fall by 21%

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Price target increased by 7.6% to US$34.44

Independent Director exercised options and sold US$616k worth of stock

Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology

Co-Founder & Chief Scientific Officer exercised options and sold US$467k worth of stock

Syndax Pharmaceuticals Announces Appointment of Steve Sabus as Chief Commercial Officer

Insufficient new directors

Consensus revenue estimates increase by 64%

Third quarter 2022 earnings released: US$0.58 loss per share (vs US$0.40 loss in 3Q 2021)

Syndax Pharmaceuticals, Inc. Announces Positive Updates to Clinical Activity and Durable Remissions in Phase 1 Portion of Augment-101 Trial of Revumenib in Patients with Acute Leukemias

Syndax Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 03, 2022

CEO & Director exercised options and sold US$549k worth of stock

President exercised options and sold US$4.4m worth of stock

Co-Founder & Chief Scientific Officer exercised options and sold US$468k worth of stock

Consensus forecasts updated

Independent Director exercised options and sold US$331k worth of stock

First half 2022 earnings released

Syndax Pharmaceuticals Q2 2022 Earnings Preview

Syndax Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Insufficient new directors

CEO & Director exercised options and sold US$464k worth of stock

President exercised options and sold US$735k worth of stock

Investor sentiment improved over the past week

Syndax Pharmaceuticals, Inc. Announces Appointment of Keith A. Goldan as Chief Financial Officer

Investor sentiment improved over the past week

Consensus forecasts updated